New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Core Insights - Myriad Genetics announced that treatment informed by the GeneSight test resulted in faster initial remission and response in patients with Major Depressive Disorder (MDD), with benefits persisting over six months [1][2][3] Group 1: Study Overview - The PRIME Care study is the largest pharmacogenomic randomized controlled trial in mental health, enrolling 1,944 U.S. Veterans with depression to assess the impact of GeneSight results on treatment outcomes [2][4] - The study found that patients whose clinicians had GeneSight results were significantly more likely to achieve remission over 24 weeks, with a 28% higher likelihood compared to the usual care group [5][6] Group 2: Post-Hoc Analysis Findings - The post-hoc analysis included 1,764 veterans and focused on the time to first remission and response, showing that GeneSight test results increased the rate of remission and response over time [3][6] - Patients who took the GeneSight test were 27% more likely to achieve remission and 21% more likely to experience a significant reduction in depressive symptoms [8] Group 3: GeneSight Test Information - The GeneSight Psychotropic test is a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health conditions, aimed at reducing the trial-and-error process in medication prescribing [7][8] Group 4: Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being through molecular tests that guide treatment decisions across various medical specialties [8][9]